Comparative Pharmacology
Head-to-head clinical analysis: CANCIDAS versus ERAXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANCIDAS versus ERAXIS.
CANCIDAS vs ERAXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Caspofungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, by noncompetitive inhibition of the enzyme β-(1,3)-D-glucan synthase, leading to osmotic instability and cell death.
Echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls, by noncompetitive inhibition of the enzyme 1,3-beta-D-glucan synthase.
70 mg IV once, followed by 50 mg IV once daily thereafter.
50 mg intravenously once daily for invasive candidiasis; 100 mg intravenously once daily for esophageal candidiasis.
None Documented
None Documented
The terminal elimination half-life is approximately 40–50 hours in adults. A multi-exponential decline is observed; the beta half-life is 9–11 hours, and the gamma (terminal) half-life is 40–50 hours. This supports once-daily dosing after a loading dose.
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), supporting once-weekly intravenous dosing.
Renal excretion of unchanged drug is minimal (approximately 1% of dose). The primary route of elimination is biliary/fecal, with about 70% of a radiolabeled dose recovered in feces over 14 days, mostly as metabolites. Urinary excretion accounts for about 10% of total radioactivity, primarily as metabolites.
Primarily excreted unchanged in feces (~70%) and urine (~10% as unchanged drug and metabolites). Biliary excretion is the major route for unchanged drug.
Category C
Category C
Echinocandin Antifungal
Echinocandin Antifungal